CN115667315A - 一种抗pd1×pdl1的双特异性抗体 - Google Patents

一种抗pd1×pdl1的双特异性抗体 Download PDF

Info

Publication number
CN115667315A
CN115667315A CN202180040152.2A CN202180040152A CN115667315A CN 115667315 A CN115667315 A CN 115667315A CN 202180040152 A CN202180040152 A CN 202180040152A CN 115667315 A CN115667315 A CN 115667315A
Authority
CN
China
Prior art keywords
seq
cancer
pdl1
linker
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040152.2A
Other languages
English (en)
Inventor
朱祯平
黄浩旻
顾昌玲
祝海霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN115667315A publication Critical patent/CN115667315A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

提供一种抗PD1×PDL1的双特异性抗体及其制备方法和用途，实验结果显示该双特异性抗体能够较好的保持各自单抗的活性，并且能够同时特异性结合PD‑1和PD‑L1两个靶点，具有良好的理化性质。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202180040152.2A 2020-06-02 2021-05-27 一种抗pd1×pdl1的双特异性抗体 Pending CN115667315A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010487619.5A CN113754773A (zh) 2020-06-02 2020-06-02 一种抗pd1×pdl1的双特异性抗体
CN2020104876195 2020-06-02
PCT/CN2021/096396 WO2021244392A1 (zh) 2020-06-02 2021-05-27 一种抗pd1×pdl1的双特异性抗体

Publications (1)

Publication Number Publication Date
CN115667315A true CN115667315A (zh) 2023-01-31

Family

ID=78782274

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010487619.5A Pending CN113754773A (zh) 2020-06-02 2020-06-02 一种抗pd1×pdl1的双特异性抗体
CN202180040152.2A Pending CN115667315A (zh) 2020-06-02 2021-05-27 一种抗pd1×pdl1的双特异性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010487619.5A Pending CN113754773A (zh) 2020-06-02 2020-06-02 一种抗pd1×pdl1的双特异性抗体

Country Status (3)

Country Link
CN (2) CN113754773A (zh)
TW (1) TW202146460A (zh)
WO (1) WO2021244392A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506863A (ja) * 2016-02-02 2019-03-14 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11046769B2 (en) * 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体

Also Published As

Publication number Publication date
WO2021244392A1 (zh) 2021-12-09
CN113754773A (zh) 2021-12-07
TW202146460A (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
US20230340097A1 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
US20210324080A1 (en) Antibody targeting ctla-4 , preparation method therefor and use thereof
CN113227151A (zh) 抗her2/pd1双特异性抗体
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
CN113754775A (zh) 一种抗pd-l1和her2的双特异性抗体
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
US11685778B2 (en) Anti-human LAG-3 monoclonal antibody and use thereof
WO2021244392A1 (zh) 一种抗pd1×pdl1的双特异性抗体
US20230257465A1 (en) ANTI-PDL1 x EGFR BISPECIFIC ANTIBODY
CN115989243A (zh) 一种抗pd-l1/vegf融合蛋白
KR102131371B1 (ko) Ang-2 특이적 항체 및 그의 용도
WO2021244552A1 (zh) 抗pdl1×kdr的双特异性抗体
US20220135686A1 (en) Antibody that binds to human pd-l1
WO2023179392A1 (zh) B7h3抗体及包含其的双功能抗体
CN113754777A (zh) 一种抗PD-L1/TGF-β融合蛋白
CN116284427A (zh) 抗muc17/cd3双特异性抗体、其制备方法及用途
CN115819596A (zh) 一种靶向人ceacam5/6的抗体、制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination